BIOCYTOGEN-B (02315) announced that the company recently entered into an option and license agreement with Acepodia Inc. (Acepodia), aiming to systematically evaluate bispecific antibody-drug conjugate (BsADC) programs through a structured assessment mechanism, thereby further accelerating the development of bispecific antibody dual-drug conjugates (BsAD2C). The agreement will grant Acepodia an option to obtain global exclusive licenses for two of BIOCYTOGEN's BsADC programs. According to the terms of the agreement, BIOCYTOGEN will be entitled to receive an upfront option payment; upon Acepodia exercising the relevant option, BIOCYTOGEN may also receive subsequent payments, including an option exercise fee, development and regulatory milestone payments, commercial milestone payments, and future sales royalties. This agreement represents a further deepening of the collaboration initiated with Acepodia earlier this year. Previously, the focus of the collaboration between the two parties was on the evaluation and screening of promising bispecific antibody and dual-payload antibody-drug conjugate (ADC) candidate programs. Based on completed preclinical research results, the company believes that combining BIOCYTOGEN's RenLite® fully human common light chain antibody development platform with Acepodia's antibody-dual-drug conjugate (AD2C) technology provides a highly promising technical pathway for the development of a new generation of BsAD2C. The expanded collaboration between the two parties aims to fully leverage the complementary advantages of their respective platforms to advance the design of a new generation of ADC molecules, with the goal of overcoming certain limitations observed in traditional ADC programs. The collaboration team is steadily progressing through key evaluation milestones for the candidate programs, and relevant advancement decisions will be made based on continuously obtained research data, combined with Acepodia's internal processes and option exercise criteria.